Citadel Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-110,550
| Closed | -$1.74M | – | 15771 |
|
|
2024
Q1 | $1.74M | Sell |
110,550
-150,738
| -58% | -$2.32M | ﹤0.01% | 5801 |
|
|
2023
Q4 | $4.21M | Buy |
261,288
+26,264
| +11% | +$335K | ﹤0.01% | 4052 |
|
|
2023
Q3 | $2.99M | Buy |
+235,024
| New | +$3.24M | ﹤0.01% | 4491 |
|
|
2023
Q2 | – | Sell |
-146,211
| Closed | -$2.26M | – | 15471 |
|
|
2023
Q1 | $2.26M | Buy |
146,211
+48,665
| +50% | +$813K | ﹤0.01% | 5135 |
|
|
2022
Q4 | $1.6M | Sell |
97,546
-103,098
| -51% | -$1.68M | ﹤0.01% | 5901 |
|
|
2022
Q3 | $3.71M | Buy |
200,644
+45,831
| +30% | +$719K | ﹤0.01% | 4389 |
|
|
2022
Q2 | $2.04M | Sell |
154,813
-24,231
| -14% | -$267K | ﹤0.01% | 5508 |
|
|
2022
Q1 | $1.66M | Buy |
179,044
+147,835
| +474% | +$1.26M | ﹤0.01% | 6506 |
|
|
2021
Q4 | $305K | Sell |
31,209
-27,418
| -47% | -$516K | ﹤0.01% | 10887 |
|
|
2021
Q3 | $1.99M | Sell |
58,627
-105,334
| -64% | -$3.36M | ﹤0.01% | 6350 |
|
|
2021
Q2 | $6M | Buy |
163,961
+157,956
| +2,630% | +$6.12M | ﹤0.01% | 4062 |
|
|
2021
Q1 | $269K | Sell |
6,005
-23,082
| -79% | -$1.07M | ﹤0.01% | 11096 |
|
|
2020
Q4 | $1.66M | Sell |
29,087
-132,414
| -82% | -$7.85M | ﹤0.01% | 5767 |
|
|
2020
Q3 | $8.29M | Buy |
161,501
+157,616
| +4,057% | +$7.72M | ﹤0.01% | 2514 |
|
|
2020
Q2 | $232K | Sell |
3,885
-422,492
| -99% | -$22.6M | ﹤0.01% | 8316 |
|
|
2020
Q1 | $17.6M | Buy |
426,377
+414,174
| +3,394% | +$23M | 0.01% | 1336 |
|
|
2019
Q4 | $760K | Sell |
12,203
-314,877
| -96% | -$15M | ﹤0.01% | 6100 |
|
|
2019
Q3 | $11.1M | Buy |
327,080
+38,083
| +13% | +$1.13M | 0.01% | 2092 |
|
|
2019
Q2 | $6.52M | Sell |
288,997
-76,019
| -21% | -$1.78M | ﹤0.01% | 2719 |
|
|
2019
Q1 | $8.47M | Sell |
365,016
-172,427
| -32% | -$4.51M | ﹤0.01% | 2267 |
|
|
2018
Q4 | $11.3M | Buy |
537,443
+221,981
| +70% | +$5.46M | 0.01% | 1762 |
|
|
2018
Q3 | $12.2M | Buy |
315,462
+287,991
| +1,048% | +$10.6M | 0.01% | 1884 |
|
|
2018
Q2 | $1.08M | Buy |
27,471
+1,134
| +4% | +$33.4K | ﹤0.01% | 5082 |
|
|
2018
Q1 | $528K | Buy |
+26,337
| New | +$667K | ﹤0.01% | 5792 |
|
|
2017
Q4 | – | Sell |
-261,436
| Closed | -$4.96M | – | 8542 |
|
|
2017
Q3 | $4.96M | Buy |
+261,436
| New | +$4.79M | ﹤0.01% | 2317 |
|
Other funds holding DCPH
Citadel Advisors's DCPH Position: Q2 2024 in Review
Citadel Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 110,550 shares — an estimated $1.74M sold.
Citadel Advisors first reported a position in DCPH in Q3 2017 and held it in 25 quarters. The position peaked at $17.6M in Q1 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Citadel Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 110,550 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $1.74M.
- Citadel Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 25 quarters.
- Citadel Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $17.6M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.